Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes.

Maitland-van der Zee AH, Stricker BH, Klungel OH, Mantel-Teeuwisse AK, Kastelein JJ, Hofman A, Leufkens HG, van Duijn CM, de Boer A.

Pharmacogenetics. 2003 Apr;13(4):219-23.

PMID:
12668918
2.

The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype.

Maitland-van der Zee AH, Stricker BH, Klungel OH, Kastelein JJ, Hofman A, Witteman JC, Breteler MM, Leufkens HG, van Duijn CM, de Boer A.

Pharmacogenetics. 2002 Nov;12(8):647-53.

PMID:
12439225
3.

Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.

Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, Donnan PT.

Pharmacogenet Genomics. 2008 Apr;18(4):279-87. doi: 10.1097/FPC.0b013e3282f60aad.

PMID:
18334912
4.

Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.

Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de Boer A.

Pharmacogenetics. 2004 Jan;14(1):53-60.

PMID:
15128051
5.

Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study.

Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM.

J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7. doi: 10.1136/jnnp.2008.150433. Epub 2008 Oct 17.

PMID:
18931004
6.

Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study.

Gumbs PD, Verschuren WM, Mantel-Teeuwisse AK, de Wit AG, Hofman A, Trienekens PH, Stricker BH, de Boer A, Klungel OH.

Drugs Aging. 2006;23(9):733-41.

PMID:
17020397
7.
8.

Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition.

Corder EH, Lannfelt L, Viitanen M, Corder LS, Manton KG, Winblad B, Basun H.

Arch Neurol. 1996 May;53(5):418-22.

PMID:
8624216
9.

A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.

Donnelly LA, Doney AS, Dannfald J, Whitley AL, Lang CC, Morris AD, Donnan PT, Palmer CN.

Pharmacogenet Genomics. 2008 Dec;18(12):1021-6. doi: 10.1097/FPC.0b013e3283106071.

PMID:
18815589
10.

Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.

Tavintharan S, Lim SC, Chan YH, Sum CF.

Diabetes Obes Metab. 2007 Jan;9(1):81-6.

PMID:
17199722
11.

Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy.

Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA.

Am J Health Syst Pharm. 2005 Jul 15;62(14):1468-75.

PMID:
15998926
12.

Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.

Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, Kokia E.

Clin Ther. 2008 Nov;30(11):2167-79. doi: 10.1016/j.clinthera.2008.11.012.

PMID:
19108805
13.

Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex.

Qiu C, Kivipelto M, Agüero-Torres H, Winblad B, Fratiglioni L.

J Neurol Neurosurg Psychiatry. 2004 Jun;75(6):828-33.

14.

Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes.

Mark L, Dani G, Fazekas O, Szüle O, Kovacs H, Katona A.

Curr Med Res Opin. 2007 Jul;23(7):1541-8.

PMID:
17559752
15.

Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999).

Mantel-Teeuwisse AK, Klungel OH, Hofman A, Verschuren WM, Trienekens PH, Porsius AJ, Stricker BH, de Boer A.

Br J Clin Pharmacol. 2006 May;61(5):592-600.

16.

Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study.

Slooter AJ, van Duijn CM, Bots ML, Ott A, Breteler MB, De Voecht J, Wehnert A, de Knijff P, Havekes LM, Grobbee DE, Van Broeckhoven C, Hofman A.

J Neural Transm Suppl. 1998;53:17-29.

PMID:
9700643
17.

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.

Peña R, Lahoz C, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A; Rap Study Group.

J Intern Med. 2002 Jun;251(6):518-25.

18.

A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization.

Valuck RJ, Williams SA, MacArthur M, Saseen JJ, Nair KV, McCollum M, Ensor JE.

Clin Ther. 2003 Nov;25(11):2936-57.

PMID:
14693317
19.

Apolipoprotein E gene polymorphism and the risk of cervical myelopathy in patients with chronic spinal cord compression.

Setzer M, Hermann E, Seifert V, Marquardt G.

Spine (Phila Pa 1976). 2008 Mar 1;33(5):497-502. doi: 10.1097/BRS.0b013e3181657cf7.

PMID:
18317192
20.

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.

Dufouil C, Richard F, Fiévet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alpérovitch A.

Neurology. 2005 May 10;64(9):1531-8.

PMID:
15883313

Supplemental Content

Support Center